In June, Chinese regulators approved the world’s first CAR-T cell therapy for solid tumour cancers, developed by a drug company based in Shanghai. One month later, at a hospital in the city, a New Zealander with advanced cancer of the stomach and small intestine became the first international patient to receive the breakthrough treatment. Chimeric antigen receptor T-cell therapy, to give it its full name, is a cutting-edge treatment that, until then, had only been approved to treat blood...
Health
China’s cancer breakthrough on CAR-T cell therapy shows progress
The Perspectives
0 verified voices · Three viewpoints · Real discourse
Only verified Neural Identity holders can participate in The Perspectives.
Sign In with Neural Identity
Left
0
Be the first to share a left perspective
Center
0
Be the first to share a center perspective
Right
0
Be the first to share a right perspective